QB3 Symposium: Innovation in Autoimmune Therapies from Discovery to Translation

​Approximately 1 in 15 people in the United States is affected by an autoimmune disease, including rheumatoid arthritis and lupus. These conditions are notoriously difficult to diagnose, and existing treatments are often hindered by non-specificity, leading to significant adverse side effects.

​Yet there is reason for optimism. Researchers have made major strides in our understanding of the immune system, including the mechanisms behind loss of immune tolerance and the development of antigen-specific therapies. This progress, combined with a surge in investment—over $2.9 billion poured into companies targeting autoimmune diseases in 2024 alone, up from $1 billion in 2023—signals a transformative moment for the field. 

​Despite these exciting strides, the unmet need for patients remains immense. This convergence of scientific breakthroughs and growing market interest inspired our team at QB3 to focus this year’s symposium on autoimmune disease research. We hope that you will join us for this in-person event.

​The symposium agenda can be found here.